Superworth

Verastem price to book ratio VSTM

Market value divided by the book value of the company's net assets, since 2012.

Today, Oct 23, 2026
18.2×
10-year median
3.3×
Against its 10-year history
95th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.5× to 85.4×
Peer median
2.5×

Verastem's price to book ratio is 18.2× as of Oct 23, 2026.

That is above its ten-year median of 3.3×, higher than on 95% of days in the last ten years.

Over that time it ranged from 0.5× in Nov 2016 to 85.4× in Apr 2020.

The median for 10 large drugmakers of a similar size is 2.5×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far18.2×4.0×18.2×
202516.1×11.5×28.2×
202414.9×2.5×22.7×
20232.5×1.3×6.1×
20221.3×1.1×4.4×
20213.9×2.6×8.0×
20202.8×1.7×85.4×
20194.8×1.0×4.8×
20182.4×2.2×12.5×
20173.0×0.5×4.3×
20160.5×0.4×0.6×
20150.6×0.5×4.9×
20142.5×1.7×3.2×
20132.4×1.9×4.8×
20121.8×1.4×2.2×

Against its peers

Companies in Drug Manufacturers - General nearest Verastem's size, closest first, today.

CompanyPrice to book ratio
VSTMVerastem18.2×
ABUSArbutus Biopharma3.2×
AMPHAmphastar Pharmaceuticals1.4×
COLLCollegium Pharmaceutical2.4×
OMEROmerosn/m
CRMDCorMedix1.3×
ZVRAZevra Therapeutics2.7×
IRWDIronwood Pharmaceuticalsn/m
PCRXPacira BioSciences2.2×
PBYIPuma Biotechnology4.1×
ANABAnaptysbio138×
Peer median2.5×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Verastem

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.